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Background: Several studies have reported the clinical effects of long-term treatment with car-
dioprotective medications in patients with lower limb peripheral arterial disease (PAD) in terms of
reducing cardiovascular morbidity and mortality. A number of these studies investigated the clinical
effect of angiotensin converting enzyme inhibitors (ACEIs) on walking distance in this group of patients.
Objective: To review the evidence regarding the effects of ACEIs in patients with symptomatic PAD of the
lower limbs in terms of the effect on maximum and pain-free walking distances and ankle brachial
pressure index (ABPI).
Methods: A systematic literature search of the medical literature from 1966 to 2010 on randomized
placebo-controlled trials which assessed the effect of ACEIs on maximum and/or pain-free walking
distances and/or ABPI in patients with symptomatic lower limbs PAD was performed. Data from included
studies were pooled with use of random-effects model with standard mean differences. Heterogeneity
across studies was assessed with calculation of I2 statistic.
Results: From a total of 346 publications identiﬁed, 34 articles were selected for full review based on title
and abstract. 4 RCTs comprising 576 patients (334(58%) males, mean age 60.7 years, age range (58e66))
met the inclusion criteria and were systematically reviewed. Of those, 137 (24%) patients suffered from
symptomatic lower limb PAD. Maximum walking distances were pooled successfully from all 4 studies.
After analysing these data, we found signiﬁcant heterogeneity among the groups and no signiﬁcant
difference in the pooled treatment effect (standard mean difference ¼ 0.46, 95% CI (0.99e1.92),
p ¼ 0.53, I2; ¼ 95%). Pain-free walking distances and ankle brachial pressure indices were pooled
successfully from 3 studies and showed an insigniﬁcant overall treatment effect (standard mean
difference ¼ 0.97, 95% CI (0.24e2.18), p ¼ 0.12 and 0.68, 95% CI (0.70e2.06), p ¼ 0.33, respectively).
Conclusion: The evidence regarding ACE inhibition efﬁcacy on treadmill walking distance in patients with
intermittent claudication is contradicting and lacked properly powered RCTs. However, based on this
study, ACEIs did not improve treadmill walking distance and ABPI in patients with symptomatic lower
limb arterial disease. Further research from properly powered RCTs is needed.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Lower limb peripheral arterial disease (PAD) is a common
disorder. An Ankle Brachial Pressure Index (ABPI)which is diagnostic
of PAD is found in approximately 12% of adults above the age of 50
years.1 Of those, almost a third experience pain on walking or inter-
mittent claudication.2 PAD is an important marker of cardiovascularvascular surgery, Academic
Inﬁrmary, Anlaby Road, Hull,
765.
hin).
ciates Ltd. Published by Elsevier Ltrisk and is associated with mortality 3e5 times that of an aged
matched population mainly due to cardiac and cerebrovascular
events. The overall prognosis for the patient with PAD is poor with
a cumulative annual mortality of up to 5%. In claudicants, however,
the prognosis for the limb is more benign with 75% of patients’
symptoms remaining stable/improving with only a small minority
progressing to critical ischaemia. It has been recommended that
patients with PAD should have aggressive secondary prevention and
management of risk factors.3e7
Over the last decade, intensive research has investigated the
potential clinical beneﬁts of angiotensin converting enzyme inhibi-
tors (ACEIs). The renin angiotensin system (RAS) plays amajor role in
cardiovascular disease. ACEIs competitively inhibit the angiotensind. All rights reserved.
Table 1
Summary of studies included in the systematic review.
Ref. No First author Year Type Jadad
score
Total No. of
patients
Type of
ACEI
Dose Follow up Outcome
16 Roberts et al 1987 RCT 4/5 23 Captopril 50 mg/day 6 months
(1 month treatment)
No effect on pain free and
maximum walking distances
17 Spence et al 1993 RCT 4/5 23 Cilazapril 2.5 mg/day 8 weeks No effect on leg blood ﬂow & adverse
effect on walking time on a treadmill
18 Overlack et al 1994 RCT 4/5 490
(54 with clinical PAD)
Perindopril 4 mg/day 6 weeks No effect on pain free and maximum
walking distances
2 Ahimastos et al 2006 RCT 5/5 40 Ramipril 10 mg/day 24 weeks Improved pain free and maximum
walking distances
34 studies selected for full text 
screening and detailed review 
4 full text studies met the inclusion 
criteria and were included in the 
systematic review 
No comparison of ACE inhibitors with 
placebo (15) 
No maximum or pain-free walking 
distances or ABPI as endpoints (2) 
Not in English language (2) 
No data for PAD patients (2) 
No inclusion of PAD patients (2) 
Duplicate publication (5) 
Not a randomised controlled trial (1) 
Treatment period <1 month (1) 
346 citations in total identified and 
screened (title, abstract, keywords) 
Fig. 1. Study ﬂow diagram of systematic review and exclusion criteria.
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REVIEWconverting enzyme which is a non speciﬁc enzyme involved in the
metabolism of many small peptides. This includes the conversion of
angiotensin I, an inactive octapeptide, into angiotensin II. Inhibition
of the angiotensin converting enzyme will reduce the levels of
angiotensin II and increase the levels of bradykinin; the latter
stimulates the synthesis of nitric oxide (NO) which plays a vital role
in vasodilatation and inhibition of vascular hypertrophy.8 ACEIs also
promote an elastogenic proﬁle in the extracellular matrix of the
arterial wall by increasing elastin and decreasing the levels of matrix
metalloproteinases.9 These effects of ACEIs improve vascular endo-
thelial function in PAD patients.
Long termACE inhibition in PAD patients with no evidence of left
ventricular dysfunction or heart failure is supported by level-1
evidenceof clinical efﬁcacy in reducing cardiovascularmorbidityand
mortality and health economic analyses of cost effectiveness.10e14
However, perhaps due to the relatively high incidence of side
effects and concerns regarding deterioration in renal function in
patientswith silent renal artery stenosis, ACE inhibition has not been
universally accepted into the arsenal of secondary prevention
measures in PAD patients. It is conceivable that increased ACEIs
prescribing in this patient group may occur if there was clear
evidence of associated improvement in disease speciﬁc symptoms.
This study aims to review the evidence supporting ACEIs use in
patients with symptomatic PAD in terms of effect on maximum
walking distance as a primary outcome measure and pain-free
walking distance and/or ABPI as secondary outcome measures.
2. Methods
2.1. Search strategy
A systematic search of literature was performed in the medical databases: MED-
LINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL). In addi-
tion,we searched conference proceedings and the reference lists of relevant articles to
identify articles missed by the electronic searches. The keywords ‘angiotensin con-
verting enzyme inhibitors,’ OR ‘angiotensin converting enzyme inhibitors,’ OR ‘ACE
inhibitors,’ AND ‘peripheral arterial disease,’ OR ‘peripheral arterial occlusive disease,’
OR ‘intermittent claudication,’ were used along with their synonyms. Limits: English
language, involving humans and randomised controlled trials were applied.
2.2. Inclusion criteria
Studies were eligible to be included in our review if they were: 1. Randomised
controlled trials which compared any kind of ACEIs with placebo or no treatment 2.
Included patients with symptomatic peripheral arterial disease of the lower limbs
(intermittent claudication) as either the study population or a subgroup 3. Used
maximum and/or pain-free walking distances and/or ABPI as outcome measures 4.
Minimumperiodof treatmentwithACEIs isonemonthand5. Published inEnglish from
1966 until present. A summary of these studies can be found in Table 1. We excluded
studies which compared ACEIs combined with any other drug with placebo.
2.3. Quality and data extraction
Quality was assessed using the Jadad ﬁve-point scale for randomised trials.15 The
followingdatawere recorded for each study: First author, yearof publication, patients’
characteristics (total number of patients, number of patients with symptomatic PAD,
age, and sex), ACEI type and dose, duration of treatment, follow up period andoutcome. Two independent reviewers (YS and FM) extracted and checked the studies
included. Disagreements between the reviewers were resolved by consensus.
Authors of one of the selected studies2 have been contacted successfully to
obtain unpublished data in order to complete a meta-analysis. In studies where
mean maximum and/or pain-free walking times were reported,2,17 they were con-
verted to distances using the treadmill speeds reported in those studies.
2.4. Statistical analysis
For both treatment groups in the included studies2,16e18 standard mean differ-
ences and 95% conﬁdence intervals were calculated based on means and standard
deviations extracted from individual studies. One study16 reportedmean and standard
error. We converted standard error to standard deviation by using a standard for-
mula.19Treatment effectwas signiﬁcant if p< 0.05. Heterogeneity between studieswas
tested with use of both the chi square test (signiﬁcant if p < 0.1) and the I2 test (with
substantial heterogeneity deﬁned as values > 50%). As studies showed signiﬁcant
heterogeneity, a random-effects model was used to calculate the pooled effect sizes.
Review Manager (version 5.0, The Cochrane Collaboration 2008) was used for
data analysis.20
3. Results
3.1. Literature search
The search identiﬁed 346 potentially eligible studies of which
312 studies were excluded on title and abstract. Full articles of the
Fig. 2. Forest plot illustrating pooled maximum treadmill walking distance. CI: conﬁdence interval, SD: standard deviation, IV: inverse variance.
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REVIEWremaining 34 studies were collected and evaluated. 4 studies met
our inclusion criteria and were included in the systematic review.
Study ﬂow diagram and exclusion criteria are presented in Fig. (1).
3.2. Patient’s characteristics
Studies included a total of 576 patients. There were 334 (58%)
males and 242 (42%) females, with a mean age of 60.7 years, age
range (58e66). 137 (24%) patients had symptomatic peripheral
arterial disease of the lower limbs (intermittent claudication).
3.3. Description of included studies
A double blind, placebo- controlled, crossover trial of antihy-
pertensive treatment in 23 patients with hypertension and
peripheral arterial disease, failed to demonstrate any statistically
signiﬁcant beneﬁt of captopril 25 mg twice daily over placebo in
terms of pain free and maximum walking distances (149  71.5 m
vs. 145 89.4 m and 228 143mvs. 226 151.9 m, respectively).16
Captopril preserved lower limb arterial circulation possibly by
maintaining the collateral blood supply which could be attributed
to the lack of angiotensin II vasoconstriction effect caused by ACE
inhibition and reduced breakdown of bradykinin.
Indeed, a placebo controlled, crossover, RCT of ACE inhibition
with cilazapril (2.5 mg/day) for 8 weeks in 23 claudicants demon-
strated a deleterious effect on treadmill walking time.17Mean
maximum treadmill walking time was longer in the placebo group
8.04  6.39 min (431  343 m) than the cilazapril group
6.05  5.01 min (325  269 m), p < 0.009. ABPI was higher, but
statistically insigniﬁcant, after treatment in the placebo group than
the cilazapril group (0.69  0.12 vs. 0.66  0.15), p > 0.05.
A multicentre, double blind, RCT of 54 patients with essential
hypertension and claudication (Fontaine IIb) randomised to peri-
ndopril 4 mg o.d (n ¼ 26) or matching placebo (n ¼ 28) for 6 weeks
found that therewasa slight butnot a statistically signiﬁcant increase
in pain-free walking distance in favour of the perindopril group
(17317mvs.16510m).18 In termsofmaximumwalkingdistance,
patients in the placebo group walked a signiﬁcantly longer distance
than the perindopril group (369 46mvs. 323 43m, respectively).
This differencewas found to be statistically insigniﬁcant according toFig. 3. Forest plot illustrating pooled pain-free treadmill walking distancethe authors. There was no difference in the ABPI in both groups after
treatment (0.75  0.05).
Finally, a further double blind trial randomised 40 intermittent
claudicants with superﬁcial femoral artery disease to either ram-
ipril 10 mg once daily or matched placebo for 24weeks (20 patients
per group) and found ramipril in comparison to placebo to be
associated with statistically signiﬁcant improvements in pain- free
walking time, 381  124 s (339  110 m) in the ramipril group vs.
161  29 s (143  26 m) in the placebo group, p < 0.001. This was
also the case for maximum treadmill walking time, 687  181 s
(611 161 m) in the ramipril group vs. 234 31.4 s (208  28 m) in
the placebo group, p < 0.001, ankle brachial pressure indices at rest
and post exercise and Walking Impairment Questionnaire scores2
The changes in ABPI with ramipril (0.73  0.09 in the ramipril
group vs. 0.50 0.10 in the placebo group, p< 0.001) were found to
be due to a reduction in brachial systolic blood pressure at rest and
both a reduction in brachial systolic blood pressure and an increase
in ankle pressure post exercise.
Ahimastos et al.2 used strict inclusion criteria which limited the
applicability of the results to non diabetic patients with infrain-
guinal arterial disease.
3.4. Outcome measures reporting
All four studies evaluated maximum walking distance/
time.2,16e18 Three studies evaluated pain free walking distance/
time2,16,18 and ABPI.2,17,18
3.5. ACEIs effect on maximum treadmill walking distance
Maximum walking distances/times were pooled successfully
from four studies.2,16e18 After analysing these data, we found
signiﬁcant heterogeneity among the groups and no signiﬁcant
difference in the pooled treatment effect (standard mean
difference ¼ 0.46, 95% CI (0.99e1.92), p ¼ 0.53, I2 ¼ 95%) (Fig. 2).
3.6. ACEIs effect on pain-free treadmill walking distance
Pain free walking distance/time could be pooled from three
studies.2,16,18 Analysis of thesedata showed signiﬁcantheterogeneity. CI: conﬁdence interval, SD: standard deviation, IV: inverse variance.
Fig. 4. Forest plot illustrating pooled Ankle Brachial Pressure Index. CI: conﬁdence interval, SD: standard deviation, IV: inverse variance.
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dardmean difference¼ 0.97, 95% CI (0.24e2.18), p¼ 0.12, I2¼ 90%)
(Fig. 3).
3.7. ACEIs effect on ABPI
Ankle Brachial Pressure Indices were also pooled from three
studies2,17,18 and analysis of data showed signiﬁcant heterogeneity
and no signiﬁcant differences in the pooled treatment effect
(standard mean difference ¼ 0.68, 95% CI (0.70e2.06), p ¼ 0.33,
I2p2; ¼ 93%) (Fig. 4).
3.8. Side effects and withdrawals due to treatment with ACEIs
In Overlack et al,18 out of 253 patients randomised to receive
perindopril, 4(1.5%) patients suffered from cough. 8 (3.2%) patients
in the perindopril group withdrew, of those, 1 patient withdrew
due to cough. Other studies did not report any side effects and/or
withdrawals due to treatment with ACEIs.
4. Discussion
This review has highlighted the contradicting evidence regarding
the impact of ACE inhibition on treadmill walking distances in
patients with PAD; as 3 out of 4 studies reported negative results;
however, these studies were not properly powered and two of them
were crossover trials.16,17 Crossover trials are not likely to be suitable
for evaluating disease progression and severity because treatment
effects are not fully reversible after each treatment. Moreover, the
variation in ﬁndings may reﬂect variability in patient subgroups,
disease distribution, and dose/duration of treatment. Long term
(>24 weeks) treatment of non diabetic patients with isolated
infrainguinal disease would seem to infer maximal beneﬁt.
Further data from properly powered randomised controlled
trials is required to analyse the effectiveness of ACEIs for symptom
relief, generic and disease speciﬁc quality of life and perhaps the
vascular endothelium in patients with intermittent claudication.
4.1. Study strengths and limitations
The strengths of this meta-analysis include a comprehensive
literature search which included only randomised controlled trials,
duplicate data extraction and duplicate assessment of quality of
evidence using the Jadad 5-point scale for randomised trials.15
Moreover, authors of unpublished data were contacted to clarify
areas of concern and to provide unreported data which consisted of
unreported means and standard deviations in one study.2 We
successfully managed to obtain unreported data from the author,
which made it possible to do a meta-analysis.
However, this meta-analysis had some limitations, including the
high heterogeneity among the included studies and the small
number of studies which have been found in the literature.
Therefore, results from this meta-analysis should be interpreted
with caution.Conﬂict of interest/funding
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